ABSTRACT
OBJECTIVES: To determine the effectiveness of botulinum toxin in a sample of patients diagnosed with greater occipital nerve neuralgia. MATERIAL AND METHODS: Twenty-nine patients (28 females, 1 male) were treated for greater occipital nerve neuralgia with onabotulinum toxin type A; the Visual Analog Pain Scale was used to determine pain severity at treatment and again 12 weeks after application. RESULTS: Average doses of onabotulinum toxin type A of 18.66±6.44 U per nerve and 35.96±12.89 U per patient were utilized. Average pain severity among the sample was 9.81±0.89 prior to botulinum toxin application and 3.68±2.31 points (p<0.0001) twelve weeks after application. Pain frequency decreased from 29.93±0.37 to 12.17±11.05 days with pain per month (p<0.0001). Six patients reported absence of pain after application (p=0.023). Dose did not correlate with the degree of clinical response observed, and no side effects were reported. CONCLUSION: Our findings suggest onabotulinum toxin type A is a safe and effective treatment alternative for patients suffering from refractory greater occipital nerve neuralgia.
Subject(s)
Botulinum Toxins, Type A , Neuralgia , Female , Headache , Humans , Male , Neuralgia/drug therapy , Spinal Nerves , Treatment OutcomeABSTRACT
OBJECTIVE: Describe findings observed in ENG of patients with spinocerebellar ataxias. METHOD: Forty-three patients were studied, and the following procedures were carried out: anamnesis, otorhinolaryngological and vestibular evaluation (ENG). RESULTS: The clinical findings in the entire group of patients were: gait disturbances (83.72%), speech difficulties (48.83%), dizziness (41.86%) and dysphagia (39.53%). Vestibular examination disclosed abnormal caloric exam (83.71%) and saccadic movements (69.76%) with the highest rates of abnormality. The overall presence of alterations in vestibular tests was (90.70%), and the most frequent finding was central vestibular disorder in (74.42%) of patients. CONCLUSION: The study showed that alterations in ENG are related to the severity of SCAs or clinical stage of the disease. We emphasize the importance of studying the vestibular system concomitantly to clinical and genetic follow up.
